PepGen Inc. remains focused on advancing its lead candidate PGN-EDODM1 for myotonic dystrophy type 1 amidst a partial FDA clinical hold affecting its FREEDOM2 trial's multiple ascending dose segment. The company’s highly specialized EDO platform underpins a differentiated therapeutic approach but is contingent on clinical progress and regulatory clearance. Liquidity remains sufficient for near-term activities though capital needs depend heavily on navigating FDA requirements, trial outcomes, and manufacturing scale-up. Long-run prospects hinge on successful trial resolution and market acceptance within the rare genetic disorder space.